Biopharmaceutical firm OncBioMune Pharmaceuticals has closed patient enrolment in the Phase I clinical trial of ProscaVax for the treatment of prostate cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ProscaVax is an immunotherapeutic vaccine candidate that combines the prostate-specific antigen (PSA) with the interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

The open-label trial enrolled a total of 20 hormone-naïve and hormone-independent patients with a reportedly progressive disease.

The trial is designed to evaluate the vaccine's safety, tolerability and effects on survivability, time to measurable disease, level of PSA in the blood, and the body's immune response to the vaccine.

See Also:

OncBioMune chief executive officer Dr Jonathan Head said: "The interim data to date has been extremely compelling, demonstrating the strong safety and tolerability profile of ProscaVax, as well as indications of efficacy with respect to slowing tumour progression and supporting an immune response to disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Based upon the data and years of previous research, we remain optimistic that ProscaVax has a future as a meaningful therapeutic for the millions of people affected by prostate cancer."

"Based upon the data and years of previous research, we remain optimistic that ProscaVax has a future as a meaningful therapeutic for the millions of people affected by prostate cancer."

The trial is being conducted at two US sites, University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, and has received funding from the US navy cancer vaccine programme.

The trial's primary objective is the measure of dose limiting adverse events from the first injection to 30 days after the last injection.

The firm has previously announced that it is avoiding the initially planned second stage of the trial due to the positive interim safety results achieved in the first stage.

Image: Histology of prostate cancer. Photo: courtesy of Otis Brawley/National Cancer Institute.